- Home
- BIIB vs HOOD Comparison
BIIB vs HOOD Comparison
Compare BIIB & HOOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- HOOD
- Stock Information
- Founded
- BIIB 1978
- HOOD 2013
- Country
- BIIB United States
- HOOD United States
- Employees
- BIIB N/A
- HOOD N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- HOOD Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- HOOD Technology
- Exchange
- BIIB Nasdaq
- HOOD Nasdaq
- Market Cap
- BIIB 18.8B
- HOOD 54.5B
- IPO Year
- BIIB 1991
- HOOD 2021
- Fundamental
- Price
- BIIB $132.82
- HOOD $93.79
- Analyst Decision
- BIIB Buy
- HOOD Buy
- Analyst Count
- BIIB 27
- HOOD 23
- Target Price
- BIIB $188.17
- HOOD $69.67
- AVG Volume (30 Days)
- BIIB 1.3M
- HOOD 51.0M
- Earning Date
- BIIB 07-31-2025
- HOOD 08-06-2025
- Dividend Yield
- BIIB N/A
- HOOD N/A
- EPS Growth
- BIIB 26.39
- HOOD 1117.91
- EPS
- BIIB 10.12
- HOOD 1.75
- Revenue
- BIIB $9,816,400,000.00
- HOOD $3,260,000,000.00
- Revenue This Year
- BIIB N/A
- HOOD $28.02
- Revenue Next Year
- BIIB N/A
- HOOD $15.11
- P/E Ratio
- BIIB $13.13
- HOOD $54.04
- Revenue Growth
- BIIB 1.59
- HOOD 59.65
- 52 Week Low
- BIIB $110.04
- HOOD $13.98
- 52 Week High
- BIIB $238.00
- HOOD $100.88
- Technical
- Relative Strength Index (RSI)
- BIIB 59.57
- HOOD 72.35
- Support Level
- BIIB $123.90
- HOOD $81.92
- Resistance Level
- BIIB $134.75
- HOOD $100.88
- Average True Range (ATR)
- BIIB 3.50
- HOOD 4.95
- MACD
- BIIB 0.28
- HOOD 1.24
- Stochastic Oscillator
- BIIB 83.71
- HOOD 77.80
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About HOOD Robinhood Markets Inc.
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fraud detection, derivatives, fractional shares, recurring investments, and others.